GlassScriptPhysician profile
Gerry A Love
NPI 1437157625
$6,584.08
in general payments reported to CMS, 2019-2025
30 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $159 · 2021: $712 · 2022: $1,173 · 2023: $2,260 · 2024: $1,071 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Travel and Lodging: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.95 |
| Travel and Lodging | $1,283.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,327.87 | 2023 | Mitraclip |
| Novartis Pharmaceuticals Corporation | $1,139.14 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.12 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $538.73 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $435.26 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $372.85 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $308.74 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $195.51 | 2021-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $175.79 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $175.22 | 2019-2022 | |
| Abiomed | $174.99 | 2020-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $174.68 | 2021-2025 | Farxiga, Brilinta, Lokelma |
| Sanofi-Aventis U.S. LLC | $153.27 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $119.41 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $98.88 | 2019-2025 | Evkeeza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $78.78 | 2019-2023 | Lexiscan |
| Kiniksa Pharmaceuticals International, Plc | $56.04 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $53.66 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $48.49 | 2025 | |
| Esperion Therapeutics, INC. | $41.18 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $37.25 | 2021 | |
| Daiichi Sankyo INC. | $32.26 | 2024-2025 | Injectafer |
| Amarin Pharma, INC. | $30.87 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $25.03 | 2025 | Opsynvi |
| Angiodynamics, INC. | $21.10 | 2024 | Angiovac |
| Medtronic, INC. | $19.53 | 2021 | |
| Altathera Pharmaceuticals LLC | $16.41 | 2022 | |
| Inspire Medical Systems, INC. | $14.76 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $12.12 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $8.14 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerry Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.